Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NASDAQ:OKYO OTCMKTS:OPTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$2.71-7.2%$3.07$2.56▼$7.73$527.03M0.212.63 million shs3.12 million shsOKYOOKYO Pharma$1.62-3.6%$1.62$1.44▼$3.35$65.70M0.0244,263 shs69,429 shsOPTIOptec International$0.00+100.0%$0.00$0.00▼$0.13$5KN/A249,756 shs1.08 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune0.00%-11.15%-10.86%-23.45%-50.64%OKYOOKYO Pharma0.00%-5.54%0.00%-2.41%-13.83%OPTIOptec International0.00%+33.33%0.00%-55.56%-81.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$2.71-7.2%$3.07$2.56▼$7.73$527.03M0.212.63 million shs3.12 million shsOKYOOKYO Pharma$1.62-3.6%$1.62$1.44▼$3.35$65.70M0.0244,263 shs69,429 shsOPTIOptec International$0.00+100.0%$0.00$0.00▼$0.13$5KN/A249,756 shs1.08 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune0.00%-11.15%-10.86%-23.45%-50.64%OKYOOKYO Pharma0.00%-5.54%0.00%-2.41%-13.83%OPTIOptec International0.00%+33.33%0.00%-55.56%-81.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.50Moderate Buy$16.67515.01% UpsideOKYOOKYO Pharma 2.40Hold$6.33290.95% UpsideOPTIOptec International 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OPTI, OKYO, IGAS, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026ALTAltimmune CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/18/2026ALTAltimmune HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00 ➝ $20.005/14/2026ALTAltimmune Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$14.00 ➝ $11.004/21/2026OKYOOKYO Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026ALTAltimmune Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/18/2026ALTAltimmune Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.003/16/2026ALTAltimmune HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$12.00 ➝ $25.00(Data available from 6/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$40K13,175.34N/AN/A$1.99 per share1.36OKYOOKYO PharmaN/AN/AN/AN/A($0.16) per shareN/AOPTIOptec InternationalN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.09M-$0.93N/AN/AN/A-214,860.98%-42.57%-35.57%8/11/2026 (Estimated)OKYOOKYO Pharma-$4.71MN/AN/AN/AN/AN/AN/AN/A8/10/2026 (Estimated)OPTIOptec InternationalN/AN/AN/AN/AN/AN/AN/AN/AN/ALatest OPTI, OKYO, IGAS, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ALTAltimmune-$0.25-$0.18+$0.07-$0.18$0.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/AOPTIOptec InternationalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmune0.1229.5629.56OKYOOKYO PharmaN/A0.58N/AOPTIOptec InternationalN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%OKYOOKYO Pharma2.97%OPTIOptec InternationalN/AInsider OwnershipCompanyInsider OwnershipALTAltimmune1.60%OKYOOKYO Pharma40.46%OPTIOptec International50.34%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune50194.47 million191.36 millionOptionableOKYOOKYO Pharma740.56 million24.15 millionNot OptionableOPTIOptec International111.65 millionN/ANot OptionableOPTI, OKYO, IGAS, and ALT HeadlinesRecent News About These CompaniesOptimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in AustraliaMay 29, 2026 | globenewswire.comDiamond Equity Research Initiates Coverage on Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN)May 27, 2026 | globenewswire.comOptec International, Inc. (OPTI) - Yahoo FinanceJuly 13, 2025 | finance.yahoo.comOptec International Inc.May 23, 2025 | barrons.comOptec Technology Ltd.April 29, 2025 | optics.orgONew Optec CEO Updates ShareholdersJanuary 16, 2025 | globenewswire.comNew Optec CEO Updates ShareholdersJanuary 16, 2025 | prismmediawire.comPGlobal Optical Current Transformer Market Size Forecasted to Surpass USD 353.0 Million Valuation by 2033, Surging at 8.4% CAGRNovember 14, 2024 | fmiblog.comFSITC International Expands Fleet with New Vessel OrdersOctober 30, 2024 | markets.businessinsider.comAston University researcher develops new optical technique that could revolutionise medical diagnosticsOctober 25, 2024 | eurekalert.orgEbit.bio Wins Landmark Patent Defence for Groundbreaking opti-ox™ Cell Programming TechnologyOctober 16, 2024 | standard-journal.comSOptical illusion psychology test: What you see first reveals if you are optimist or too cautious in lifeOctober 4, 2024 | timesofindia.indiatimes.comOpti Digital Welcomes Guillem Fiter as Chief Marketing OfficerSeptember 17, 2024 | exchangewire.comEOGP exhibiting exciting lineup of metrology systems at IMTS 2024September 5, 2024 | insights.globalspec.comIAndersen Global Enters Japan with the Collaborating Firm OptiAugust 30, 2024 | tmcnet.comThe Optical Women’s Association Announces Global Connection Event at Silmo ParisAugust 29, 2024 | invisionmag.comIOptical Communication and Networking Equipment Market to Reach $54.0 Billion, Globally, by 2032 at 8.7% CAGR: Allied Market ResearchAugust 20, 2024 | tmcnet.comEngineers bring efficient optical neural networks into focusAugust 14, 2024 | sciencedaily.comSOptical navigation tech could streamline planetary explorationAugust 7, 2024 | msn.comIso-propagation vortices: optical multiplexing for unprecedented information capacityMay 17, 2024 | eurekalert.orgENew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhy Applied Optoelectronics Stock May Be Near a Turning PointBy Thomas Hughes | May 18, 2026Zscaler Stock Drops 30%: Why the Dip Is a Buy OpportunityBy Thomas Hughes | May 27, 2026Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong MomentumBy Chris Markoch | May 10, 2026The Power Grid Is Dying—Is It Time to Buy Its Replacement?By Jeffrey Neal Johnson | May 15, 2026Quantum Computing's Commercial Breakout Has ArrivedBy Jeffrey Neal Johnson | May 27, 2026OPTI, OKYO, IGAS, and ALT Company DescriptionsAltimmune NASDAQ:ALT$2.71 -0.21 (-7.19%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$2.70 0.00 (-0.18%) As of 06/5/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.OKYO Pharma NASDAQ:OKYO$1.62 -0.06 (-3.57%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$1.62 +0.00 (+0.06%) As of 06/5/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.Optec International OTCMKTS:OPTI$0.0004 +0.00 (+100.00%) As of 06/5/2026 03:39 PM EasternOptec International, Inc. engages in selling and marketing optimized fuel maximizer units in North America and internationally. It markets optimized fuel maximizer for passenger vehicles, intermediate/medium duty trucks, off-road equipment, generator systems, heavy duty diesel on-road vehicles, and transportation refrigeration units. The company was formerly known as Green Meadow Products, Inc. and changed its name to Optec International, Inc. in August 2017. Optec International, Inc. was founded in 2012 and is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Petco Faces Tough Competition, But Momentum Is Building IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
